(Companies Covered: F. Hoffmann-La Roche Ltd, Hetero, GlaxoSmithKline, Eli Lilly and Company, Pfizer, Alnylam Pharmaceuticals, Allergan plc, Biocon Limited, Bristol-Myers Squibb Company)
The global cervical cancer drugs market is expected to decline from $8.4 billion in 2019 to $7.4 billion in 2020 at a compound annual growth rate of -11.3%. The decline is mainly due to the COVID-19 outbreak and the measures to contain it. Hospitals across the world have postponed the chemo treatments for cancer patients due to covid positive cases in the hospitals. The sessions are delayed or postponed to prevent patients and staff from unnecessary exposure. The cancer treatment can lower the patient`s ability to fight infection. COVID-19 pandemic is affecting industries across the globe including the pharmaceutical sector. The disruptions due to extended factory closures in various countries, shortage of APIs and other chemicals, rise in prices of key ingredients, and slowed production are the key factors for this decline. The market is then expected to recover and grow at a compound annual growth rate of 5.3% from 2021 and reach $10.5 billion in 2023.
Read More On The Global Cervical Cancer Drugs Market Report At –
The cervical cancer drugs market consists of sales of cervical cancer drugs used for the treatment of cervical cancer in women. The cervical cancer is the medical condition in which there is a tumor formation in the lower portion of uterus which is known as cervix.
Global Cervical Cancer Drugs Market Segmentation –
1) By Cancer Type: Squamous Cell Cancer, Adenocarcinoma.
2) By Drug Type: Avastin, Bevacizumb, Blemocin, Blenoxane, Others.
3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Others.
Global Cervical Cancer Drugs Market Driver –
The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market. Women with HIV positive have a greater risk of cervical cancer than the general population. Nearly 18 million women have tested HIV positive globally, HIV weakens the immune system which increases the likelihood of cervical cancer. Women with HIV have an increased chance of being diagnosed with cervical cancer because the count of the protein CD4 goes down.
Request For A Sample Of The Global Cervical Cancer Drugs Market Report At –
Few Points From The Global Cervical Cancer Drugs Market TOC
1. Executive Summary
2. Cervical Cancer Drugs Market Characteristics
3. Cervical Cancer Drugs Market Size And Growth
3.1. Global Cervical Cancer Drugs Historic Market, 2015-2019, $ Billion
4. Cervical Cancer Drugs Market Segmentation
4.1. Global Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2023F,
2025F, 2030F, $ Billion
5. Cervical Cancer Drugs Market Regional And Country Analysis
5.1. Global Cervical Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6. Asia-Pacific Cervical Cancer Drugs Market
6.1. Asia-Pacific Cervical Cancer Drugs Market Overview
6.2. Asia-Pacific Cervical Cancer Drugs Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
Company Name: The Business Research Company
Contact Person: Oliver Guirdham
Email: Send Email
Phone: +44 20 7193 0708
State: Greater London
Country: United Kingdom